<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55420">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02027532</url>
  </required_header>
  <id_info>
    <org_study_id>09-060</org_study_id>
    <nct_id>NCT02027532</nct_id>
    <nct_alias>NCT01029457</nct_alias>
  </id_info>
  <brief_title>Prevention of Infection in Closed Fractures: Cefazolin Versus Vancomycin</brief_title>
  <official_title>Prevention of Infection in Surgical Treatment of Closed Fractures: A Comparative Study of Cefazolin Versus Vancomycin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Tennessee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Tennessee</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the incidence rate of infection in surgical patients
      with closed fractures treated prophylactically with Cefazolin versus Vancomycin in the
      peri-operative period.

      The hypothesis of this study is that patients undergoing surgical treatment for closed
      fractures who are treated prophylactically with Vancomycin will have a lower incidence rate
      of infection than patients who are treated prophylactically with Cefazolin.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>October 2009</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>incidence of infection</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Infection</condition>
  <condition>Closed Fractures</condition>
  <arm_group>
    <arm_group_label>Cefazolin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravenous, weight-based dose (1gm&lt;80kg, 2gm&gt;80kg), perioperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravenous, weight-based dose (1gm&lt;80kg, 2gm&gt;80kg), perioperatively</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefazolin</intervention_name>
    <arm_group_label>Cefazolin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <arm_group_label>Vancomycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 18 years old and 85 years old

          -  Closed fracture

          -  Fracture treatment plan is for one operation on one day (one surgical setting)

          -  Likely to follow-up with surgeon until fracture is healed

          -  Ability to understand and agree to Informed Consent

        Exclusion Criteria:

          -  Under 18 years old or over 85 years old

          -  Open fracture(s)

          -  Fracture requires multiple operations

          -  Other injuries requiring operations

          -  Documented allergy to Cefazolin or Vancomycin

          -  Previous history of Methicillin-resistant Staphylococcus aureus infection

          -  Previous surgery on the injured extremity within 1 year

          -  Use of antibiotics within 2 weeks before or after injury

          -  Use of antibiotics within 2 weeks before surgery

          -  Unlikely to follow-up until fracture is healed

          -  Unable to understand and agree to Informed Consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter J Nowotarski, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UTCOM Chattanooga/Erlanger Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Erlanger Health System</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 2, 2014</lastchanged_date>
  <firstreceived_date>January 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Fractures, Closed</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cefazolin</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
